Surmodics, Inc. (SRDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
SRDX POWR Grades
- SRDX scores best on the Quality dimension, with a Quality rank ahead of 98.09% of US stocks.
- The strongest trend for SRDX is in Growth, which has been heading up over the past 31 weeks.
- SRDX ranks lowest in Momentum; there it ranks in the 42nd percentile.
SRDX Stock Summary
- With a price/earnings ratio of 102.41, Surmodics Inc P/E ratio is greater than that of about 91.27% of stocks in our set with positive earnings.
- The ratio of debt to operating expenses for Surmodics Inc is higher than it is for about merely 0.49% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.26 for Surmodics Inc; that's greater than it is for only 14.92% of US stocks.
- If you're looking for stocks that are quantitatively similar to Surmodics Inc, a group of peers worth examining would be AMSWA, NTCT, DSGX, LMAT, and BHE.
- SRDX's SEC filings can be seen here. And to visit Surmodics Inc's official web site, go to www.surmodics.com.
SRDX Valuation Summary
- SRDX's EV/EBIT ratio is 81.8; this is 186.51% higher than that of the median Healthcare stock.
- SRDX's price/earnings ratio has moved down 71.8 over the prior 243 months.
- SRDX's price/earnings ratio has moved down 71.8 over the prior 243 months.
Below are key valuation metrics over time for SRDX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SRDX | 2019-04-09 | 7.4 | 5.6 | -401.9 | -107.1 |
| SRDX | 2017-03-20 | 4.4 | 3.0 | 32.9 | 17.7 |
| SRDX | 2014-04-03 | 5.6 | 3.5 | 21.6 | 15.2 |
| SRDX | 2011-05-17 | 4.0 | 1.7 | -10.1 | -9.6 |
| SRDX | 2007-09-05 | 12.0 | 6.1 | 35.3 | 21.9 |
| SRDX | 2002-03-05 | 25.4 | 10.6 | 117.8 | 66.8 |
SRDX Growth Metrics
- Its 5 year cash and equivalents growth rate is now at -72.64%.
- Its year over year net income to common stockholders growth rate is now at 10.5%.
- Its 5 year price growth rate is now at 76.8%.
The table below shows SRDX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-03-31 | 106.718 | 24.498 | 7.326 |
| 2020-12-31 | 94.545 | 10.649 | 0.701 |
| 2020-09-30 | 94.864 | 14.01 | 1.123 |
| 2020-06-30 | 103.137 | 25.216 | 7.623 |
| 2020-03-31 | 100.598 | 13.233 | 6.63 |
| 2019-12-31 | 100.452 | 12.534 | 6.43 |
SRDX Price Target
For more insight on analysts targets of SRDX, see our SRDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $74.25 | Average Broker Recommendation | 1.25 (Strong Buy) |
SRDX Stock Price Chart Interactive Chart >
SRDX Price/Volume Stats
| Current price | $54.54 | 52-week high | $59.75 |
| Prev. close | $54.92 | 52-week low | $35.17 |
| Day low | $54.24 | Volume | 18,600 |
| Day high | $56.15 | Avg. volume | 46,726 |
| 50-day MA | $53.42 | Dividend yield | N/A |
| 200-day MA | $48.68 | Market Cap | 756.36M |
Surmodics, Inc. (SRDX) Company Bio
SurModics Inc. provides surface modification and in vitro diagnostic technologies to the healthcare industry. The company operates through two segments, Medical Device and In Vitro Diagnostics. The company was founded in 1979 and is based in Eden Prairie, Minnesota.
SRDX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $54.54 | $11.71 | -78% |
Below please find a table outlining a discounted cash flow forecast for SRDX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Surmodics Inc ranked in the 20th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Surmodics Inc ended up being:
- The compound growth rate in the free cash flow of Surmodics Inc over the past 5.73 years is 0.04%; that's higher than only 24.41% of free cash flow generating stocks in the Healthcare sector.
- SRDX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 63.85% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -79% |
| 1% | -78% |
| 2% | -78% |
| 3% | -78% |
| 4% | -78% |
| 5% | -78% |
Want more companies with a valuation profile/forecast similar to that of Surmodics Inc? See ARWR, LGND, ILMN, EW, and MD.
Latest SRDX News From Around the Web
Below are the latest news stories about Surmodics Inc that investors may wish to consider to help them evaluate SRDX as an investment opportunity.
HRC vs. SRDX: Which Stock Should Value Investors Buy Now?HRC vs. SRDX: Which Stock Is the Better Value Option? |
Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story... |
Surmodics (SRDX) Boosts Portfolio With Vetex Medical BuyoutSurmodics' (SRDX) buyout of Vetex Medical adds second FDA 510 (k) cleared device to its thrombectomy platform. |
Surmodics Builds Thrombectomy Portfolio with Acquisition of Vetex Medical LimitedEDEN PRAIRIE, Minn., July 06, 2021--Surmodics Builds Thrombectomy Portfolio with Acquisition of Vetex Medical Limited |
HRC vs. SRDX: Which Stock Is the Better Value Option?HRC vs. SRDX: Which Stock Is the Better Value Option? |
SRDX Price Returns
| 1-mo | -0.78% |
| 3-mo | -7.72% |
| 6-mo | 20.16% |
| 1-year | 12.50% |
| 3-year | -8.03% |
| 5-year | 110.99% |
| YTD | 25.32% |
| 2020 | 5.04% |
| 2019 | -12.34% |
| 2018 | 68.79% |
| 2017 | 10.24% |
| 2016 | 25.31% |
Continue Researching SRDX
Here are a few links from around the web to help you further your research on Surmodics Inc's stock as an investment opportunity:Surmodics Inc (SRDX) Stock Price | Nasdaq
Surmodics Inc (SRDX) Stock Quote, History and News - Yahoo Finance
Surmodics Inc (SRDX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...